Prosecution Insights
Last updated: November 12, 2026

Nucaps Nanotechnology S L

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Nucaps Nanotechnology S L has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution effort for the company's current filings. The focus on a single examiner suggests that the company's pharmaceutical or biotechnological research is currently being evaluated through a single point of contact at the patent office.

The busiest examiner identified is ABBAS, ABDULRAHMAN MUSTAFA, who is currently handling 1 pending office action. Because the total pending office actions for the company is 1, this examiner manages the entirety of the active workload. This distribution means that the company's immediate prosecution outcomes in the Biotechnology & Pharmaceuticals sector are tied directly to the feedback and examination style of ABBAS, ABDULRAHMAN MUSTAFA.

Practitioners should note that having 1 distinct art unit and 1 distinct examiner for the 1 pending office action simplifies the administrative process. There are no competing priorities or different examination standards to balance across the portfolio. This focused profile allows the applicant to dedicate all resources to addressing the specific issues raised in the single pending office action within the assigned art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ABBAS, ABDULRAHMAN MUSTAFA 1 52.2% +28.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18634670 Encapsulated phytomedicines for use against cancer ABBAS, ABDULRAHMAN MUSTAFA —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18634670 Encapsulated phytomedicines for use against cancer ABBAS, ABDULRAHMAN MUSTAFA —

Top Art Units

Art UnitApps
1612 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18634670 Encapsulated phytomedicines for use against cancer ABBAS, ABDULRAHMAN MUSTAFA 1612 §103§112 Non-Final OA — Pending Apr 12, 2024

Managing Nucaps Nanotechnology S L's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Nucaps Nanotechnology S L have?

Nucaps Nanotechnology S L has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Nucaps Nanotechnology S L applications?

Abdulrahman Mustafa Abbas has the most, with 1 of Nucaps Nanotechnology S L's pending office actions.

What technology area are Nucaps Nanotechnology S L's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month